Le Lézard
Classified in: Health
Subject: TRI

Gencove announces Phase I SBIR grant to validate polygenic risk score estimation from low-pass sequencing


NEW YORK, April 25, 2019 /PRNewswire/ -- Gencove, the leading low-pass sequencing platform announced today the receipt of a Phase I grant from the National Human Genome Research Institute under the auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health. The grant will be used to validate methods for accurate calculation of polygenic risk scores from low-pass sequencing data that allow for population-scale screening applications, with a first application to coronary artery disease.

As clinical evidence for the benefit of screening patients for polygenic risk of diseases continues to accumulate, there will be increasing need for a scalable and flexible assay to measure these scores. Gencove's low-pass genome sequencing combined with its imputation algorithms can address the technological challenge to provide a highly accurate estimate of a polygenic risk score across ethnic groups using an assay that can scale financially and operationally to entire health care systems. Low-pass sequencing is an approach to combine the throughput and cost-effectiveness of genotyping arrays with the accuracy and population portability of whole genome sequencing.

Regarding this award, Gencove's CEO Joe Pickrell said, "The flexibility, operational efficiency, cost-effectiveness, and population-agnostic nature of low-pass sequencing make it a great choice for calculating polygenic risk scores at scale."

Gencove has recently raised a $3.2 million investment led by Spero Ventures.

About Gencove

Gencove is a spin-out of the New York Genome Center dedicated to making genomic data more accessible and interpretable through the development of molecular and computational tools. Gencove's flagship product is its low-pass genome sequencing platform; the company operates a laboratory in New York and offers both low-pass sequencing and analytics software as a service, with customers that include top academic institutions, biotechnology and pharmaceutical companies. More information is available at www.gencove.com.

Contact: Maria Vazquez, maria.vazquez@gencove.com

SOURCE Gencove


These press releases may also interest you

at 19:08
About this marketThe rise in several clinical trials in developing countries is one of the key factors anticipated to trigger market growth during the forecast period. Stringent drug development regulations in the US have negatively affected the...

at 19:00
The "Animal Biotechnology - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. This report describes and evaluates animal biotechnology and its application in veterinary medicine...

at 18:45
The "Proteomics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. This report describes and evaluates the proteomic technologies that will play an important role in drug...

at 18:30
RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AAC Holdings, Inc. ("AAC" or the "Company") between March 8, 2017 and April 15, 2019, inclusive (the "Class Period")....

at 18:30
The "Neuroprotection - Methods, Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the...

at 18:10
Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that an abstract describing clinical data regarding their lysine-specific demethylase (LSD1)...



News published on 25 april 2019 at 21:17 and distributed by: